Nasopharyngeal carcinoma
Conditions
Interventions
Experimental group:Immunotherapy combined with chemotherapy (GP regimen) + carrilizumab
Sponsors
West District of the First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years, no gender limit; 2. Patients with N2 or N3 or T4 nasopharyngeal carcinoma confirmed by pathology or histology; 3. At least one measurable lesion (spiral CT >=10mm, meeting RECIST 1.1 criteria); 4. ECOG score: 0-1; 5. Expected survival >= 3 months; 6. If the major organs function normally, the following criteria are met: (1) The standard of routine blood examination shall meet (no blood transfusion or blood products within 14 days) : WBC >= 4x10^9 /L, HB>=90 g/L, ANC>=1.5x10^9/L, PLT>=80x10^9/L; (2) Biochemical examination should meet the following criteria: TBIL 45 ml/min (Cockcroft-Gault formula); 7. The patients voluntarily joined the study and signed the informed consent with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Previous history of radiotherapy or chemotherapy; 2. History of immunodeficiency diseases; 3. Patients with severe uncontrollable infection; 4. High doses of glucocorticoids, anticancer monoclonal antibodies, or other immunosuppressants within 4 weeks; 5. Pregnancy or lactation; 6. Known hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophiliacs, coagulation disorders, thrombocytopenia, etc.); 7. A history of allergy to any component of carrilizumab, gemcitabine, cisplatin and other platinum-based drugs; 8. Other conditions considered by the researchers to be ineligible for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival; Progression Free Survival;Disease Control Rate;2-year Overall Survival (OS) Rate;Adverse Event; | — |
Countries
China
Contacts
Public ContactGao Jin
West District of the First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed